Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-08
2008-04-08
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S120000
Reexamination Certificate
active
07354929
ABSTRACT:
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
REFERENCES:
patent: 4925846 (1990-05-01), Deacon et al.
patent: 4944790 (1990-07-01), Moser et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5744491 (1998-04-01), Boigegrain et al.
patent: 5744493 (1998-04-01), Boigegrain et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6100259 (2000-08-01), Xiang et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 6355631 (2002-03-01), Bouchard et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6444816 (2002-09-01), Das et al.
patent: 6476060 (2002-11-01), Lange et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2001/0053788 (2001-12-01), Lange et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0019421 (2002-02-01), Biberman et al.
patent: 2002/0035102 (2002-03-01), Achard et al.
patent: 2002/0091114 (2002-07-01), Plot-Grosjean et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2002/0128302 (2002-09-01), Maruanl et al.
patent: 2002/0188007 (2002-12-01), Barth et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2003/0139386 (2003-07-01), Cote et al.
patent: 2003/0199536 (2003-10-01), Thomas et al.
patent: 2004/0077650 (2004-04-01), Dow
patent: 2004/0092520 (2004-05-01), Griffith
patent: 2004/0122074 (2004-06-01), Dow et al.
patent: 2004/0157839 (2004-08-01), Griffith
patent: 2004/0214837 (2004-10-01), Griffith
patent: 2004/0214855 (2004-10-01), Carpino et al.
patent: 2004/0214856 (2004-10-01), Carpino et al.
patent: 1354884 (2003-11-01), None
patent: WO9602248 (1996-02-01), None
patent: 00/14088 (2000-03-01), None
patent: WO0014088 (2000-03-01), None
patent: WO0015609 (2000-03-01), None
patent: WO03082833 (2000-10-01), None
patent: WO01029007 (2001-04-01), None
patent: WO01032629 (2001-05-01), None
patent: WO01032663 (2001-05-01), None
patent: WO0185092 (2001-11-01), None
patent: WO03006007 (2002-01-01), None
patent: WO02053565 (2002-07-01), None
patent: WO02074312 (2002-09-01), None
patent: WO02076949 (2002-10-01), None
patent: WO03007887 (2003-01-01), None
patent: WO03018060 (2003-03-01), None
patent: WO03020217 (2003-03-01), None
patent: WO03020314 (2003-03-01), None
patent: WO03027069 (2003-04-01), None
patent: WO03027076 (2003-04-01), None
patent: WO03027114 (2003-04-01), None
patent: WO03028648 (2003-04-01), None
patent: WO03037890 (2003-05-01), None
patent: WO03040107 (2003-05-01), None
patent: WO03051850 (2003-06-01), None
patent: WO03051851 (2003-06-01), None
patent: WO03075660 (2003-09-01), None
patent: WO03077847 (2003-09-01), None
patent: WO03078413 (2003-09-01), None
patent: WO3080609 (2003-10-01), None
patent: WO03082190 (2003-10-01), None
patent: WO03082191 (2003-10-01), None
patent: WO03082256 (2003-10-01), None
patent: WO03084943 (2003-10-01), None
patent: WO03086288 (2003-10-01), None
patent: WO03087037 (2003-10-01), None
patent: WO03095455 (2003-11-01), None
patent: WO2004012617 (2004-02-01), None
Arnone, M., et al., “Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagnoist of Central Cannabinoid (CB1) Receptors”,Psychopharmacology, vol. 132, pp. 104-106, (1997).
Basavarajappa, B.S., et al., Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane,Brain Research, vol. 793, pp. 212-218 (1998).
Birkofer, L. et al., “Silyl-Derivate von Pyrazol, Isoxazol und 1,2,3-Triazol”,Chem. Ber., vol. 112, pp. 2829-2836 (1979).
Cusamo, G., et al., “Synthesis of 2-H-pyrazolo 34-clquinollne derivatives by one pot rearrangement of phenyhydroazones of 3-acylindoles”,Heterocycles, vol. 24, No. 11, pp. 3181-3186 (1988).
Chaperon, F., et al., “Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats”,Psychopharmacology, vol. 135, pp. 324-332 (1998).
Colombo, G., et al., “Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716”,Life Sciences, vol. 63, pp. PL113-PL117 (1998).
Compton, D.R., et al., “In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A); Inhibition of Delta-9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity”,Journal of Pharmacology Experimental Therapy, vol. 277, pp. 586-594 (1996).
Croci, T., et al.,British Journal of Pharmacology, “Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor—{acute over (α)} In the Gut and Systemic Anti-Inflammatory Activity of SR 141716 (Rimonabant) in Rodents”, vol. 140, pp. 115-122 (2003).
DaSilva, G.E., et al., “Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats”,Neuroscience Letters, vol. 23, No. 6, pp. 2453-2458 (2003).
Dewey, W.L., Cannabinoid Pharmacoloty,Phramacological Reviews, vol. 38, No. 2, pp. 151-178 (1986).
Drummond, J., et al., “Evaluation and Synthesis of Aminohydroxiyisoxazoles and Pyrazoles as Potential Glycine Agonists”,Jounral of Medicinal Chemistry, vol. 32, pp. 2116-2128 (1989).
Dutta, A., et al., “synthesis and Phramacological Evaluation of the Cannabinoid Antagonist SR 141716A”,Medicinal Chemistry Reviews, vol. 5, pp. 54-62 (1994).
Franke, H., et al., “Polare Cycloadditionen von elektronenreichen Mehrfach-bindungssystemen an 1,3,4-oxadiazolium-Salze: Synthese von 3aH-[1,3,4]Oxadlazolo[3,2-a]chinolinen”Chen. Ber., vol. 112, pp. 3623-3636, (1979).
Freedland, C.S., et al., “Effects of SR1417A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding”,Pharmacological Biochemical Behaviors, vol. 67, pp. 265-270 (2000).
Gifford, A.N., et al., Electrically Evoked Acethichollne Release fron Hippocampal Silices Is Inhibited by the Cannabinoid Receptor Agonist, WIN 55212-2 and is Potentiated by the Cannabinoid Antagonist, SR 141716A,J. Phramcolo. Exp. Ther., vol. 277, pp. 1431-1436 (1996).
Gomez, R., et al., “A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding”,Journal of Neurosciences, vol. 22, No. 21 ,m pp. 9612-9617, (2002).
Howlett, A.C., et al., International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors,Pharmcology Reviews, vol. 54, pp. 161-202 (2002).
Hungund, B.L. et al., “Are Anadamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence”,Alcohol & Alcoholism, vol. 35, No. 2, pp. 126-133 (2000).
Lan, R., et al., “Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists”,Journal of Medicinal Chemistry, vol. 42, pp. 769-776 (1999).
Lellemand, F., et al., Effects of CB1 Cannablnoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration, Alcohol Clin. Exp. Research, vol. 25, No. 9, pp. 1317-1323 (2001).
Lichtman, A.H., et al., “Delta-9-Tetrahydrocannabinol Impairs Spatial Memory through a Cannabinoid Receptor Mechanism”,Psychopharmacology, vol. 7, pp. 65-71 (1996).
Mansbach, R.S., et al.,Psychopharmacology, “Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behavior of Pigeons and Rats”, vol. 124, pp. 315-322 (1996).
Murray, W., et al., “A Simple Regioselective Synthesis of Ethyl 1,5-Diarytpyrazole-3-carboxylates”,J. Heterocyclic Chem., vol. 26, p. 1389 (1989).
Perlo, A., et al., Central Mediation of the Cannabinoid Cue: A
Carpino Philip A.
Griffith David A.
Benson Gregg C.
Musser Arlene K.
Pfizer Inc.
Rahmani Niloofar
Seaman Margaret D.
LandOfFree
Cannabinoid receptor ligands and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cannabinoid receptor ligands and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cannabinoid receptor ligands and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2772631